8-K Announcements
6Material company update
Apr 27, 2026·SEC
Material company update
Mar 6, 2026·SEC
Material company update
Mar 5, 2026·SEC
CorMedix Inc.(CRMD)Earnings, Financials & Key Ratios
CRMD•NASDAQ
$8.05
$631M mkt cap·3.9× P/E·Price updated May 6, 2026
AboutCorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Show more
- Revenue$312M+617.0%
- EBITDA$165M+849.0%
- Net Income$163M+1009.4%
- EPS (Diluted)2.04+780.0%
- Gross Margin88.46%-4.5%
- EBITDA Margin52.98%+204.5%
- Operating Margin48.17%+193.7%
- Net Margin52.31%+226.8%
- ROE66.56%+387.3%
- ROIC49.72%+206.3%
- Debt/Equity0.37+5916.2%
- Interest Coverage53.97+110.2%
CRMD Key Insights
CorMedix Inc. (CRMD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 55.4% free cash flow margin
- ✓Strong 5Y sales CAGR of 319.7%
✗Weaknesses
- ✗Shares diluted 36.4% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CRMD Price & Volume
CorMedix Inc. (CRMD) stock price & volume — 10-year historical chart
Loading chart...
CRMD Growth Metrics
CorMedix Inc. (CRMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years107.55%
5 Years319.75%
3 Years1582.83%
TTM617.03%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM1009.4%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM708.19%
Return on Capital
10 Years-102.43%
5 Years-34.18%
3 Years-21.82%
Last Year40.75%
CRMD Recent Earnings
CorMedix Inc. (CRMD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 3/12 qtrs (38%)
Q2 2026Latest
Mar 5, 2026EPS
$0.61
Est $0.86
-29.1%
Revenue
$129M
Est $127M
+1.3%
Q4 2025
Nov 12, 2025EPS
$0.57
Est $0.48
+18.8%
Revenue
$104M
Est $127M
-17.9%
Q3 2025
Aug 7, 2025EPS
$0.28
Est $0.20
+40.0%
Revenue
$40M
Est $42M
-6.4%
Q2 2025
May 6, 2025EPS
$0.30
Est $0.25
+20.0%
Revenue
$39M
Est $30M
+30.8%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 5, 2026 | $0.61vs $0.86-29.1% | $129Mvs $127M+1.3% |
| Q4 2025 | Nov 12, 2025 | $0.57vs $0.48+18.8% | $104Mvs $127M-17.9% |
| Q3 2025 | Aug 7, 2025 | $0.28vs $0.20+40.0% | $40Mvs $42M-6.4% |
| Q2 2025 | May 6, 2025 | $0.30vs $0.25+20.0% | $39Mvs $30M+30.8% |
Based on last 12 quarters of dataView full earnings history →
CRMD Peer Comparison
CorMedix Inc. (CRMD) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 SUPN | 2.96B | 51.45 | -75.66 | 8.63% | -3.74% | -2.73% | 0.04 | |
 PCRX | 931.85M | 23.69 | 148.06 | 3.63% | 1.27% | 1.31% | 0.66 | |
 AVNS | 1.15B | 24.72 | -16.93 | 1.95% | -9.69% | -8.91% | 0.17 | |
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 |
Compare CRMD vs Peers
CorMedix Inc. (CRMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CRMD Income Statement
CorMedix Inc. (CRMD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 329.33K | 429.8K | 283.27K | 239.23K | 190.94K | 65.41K | 0 | 43.47M | 311.71M |
| Revenue Growth % | 46.95% | 30.51% | -34.09% | -15.55% | -20.19% | -65.74% | -100% | - | 617.03% |
| Cost of Goods Sold | 114.96K | 396.79K | 373.23K | 204.85K | 148.94K | 3.73K | 205.56K | 3.19M | 35.96M |
| COGS % of Revenue | 34.91% | 92.32% | 131.76% | 85.63% | 78% | 5.71% | - | 7.34% | 11.54% |
| Gross Profit | 214.36K▲ 0% | 33.01K▼ 84.6% | -89.97K▼ 372.5% | 34.38K▲ 138.2% | 42K▲ 22.1% | 61.67K▲ 46.8% | -205.56K▼ 433.3% | 40.28M▲ 19695.9% | 275.75M▲ 584.6% |
| Gross Margin % | 65.09% | 7.68% | -31.76% | 14.37% | 22% | 94.29% | - | 92.66% | 88.46% |
| Gross Profit Growth % | 250.36% | -84.6% | -372.54% | 138.22% | 22.14% | 46.85% | -433.3% | 19695.86% | 584.55% |
| Operating Expenses | 33.14M | 26.9M | 20.92M | 27.26M | 29.48M | 30.69M | 48.75M | 62.64M | 125.61M |
| OpEx % of Revenue | 10062.48% | 6258.12% | 7384.55% | 11392.81% | 15439.51% | 46914.2% | - | 144.09% | 40.3% |
| Selling, General & Admin | 8.65M | 8.07M | 0 | 13.88M | 16.35M | 20.01M | 35.6M | 58.7M | 30.17M |
| SG&A % of Revenue | 2627.28% | 1878.73% | - | 5801.06% | 8561.3% | 30586.61% | - | 135.02% | 9.68% |
| Research & Development | 24.49M | 18.82M | 11.05M | 13.38M | 13.13M | 10.68M | 13.16M | 3.94M | 19.33M |
| R&D % of Revenue | 7435.2% | 4379.39% | 3901.95% | 5591.75% | 6878.21% | 16327.59% | - | 9.07% | 6.2% |
| Other Operating Expenses | 0 | 0 | 9.87M | 0 | 0 | 0 | 0 | 0 | 76.11M |
| Operating Income | -32.92M▲ 0% | -26.86M▲ 18.4% | -21.01M▲ 21.8% | -27.22M▼ 29.6% | -29.44M▼ 8.1% | -30.62M▼ 4.0% | -48.96M▼ 59.9% | -22.36M▲ 54.3% | 150.14M▲ 771.6% |
| Operating Margin % | -9997.39% | -6250.44% | -7416.31% | -11378.44% | -15417.51% | -46819.91% | - | -51.43% | 48.17% |
| Operating Income Growth % | -32.97% | 18.41% | 21.8% | -29.57% | -8.14% | -4.03% | -59.87% | 54.34% | 771.58% |
| EBITDA | -32.89M | -26.79M | -20.93M | -27.08M | -29.26M | -30.41M | -48.89M | -22.05M | 165.13M |
| EBITDA Margin % | -9986.19% | -6233.17% | -7390.44% | -11318.46% | -15324.8% | -46500.32% | - | -50.71% | 52.98% |
| EBITDA Growth % | -32.96% | 18.54% | 21.86% | -29.34% | -8.06% | -3.95% | -60.73% | 54.9% | 849% |
| D&A (Non-Cash Add-back) | 36.89K | 74.22K | 73.29K | 143.49K | 177.02K | 209.04K | 70.75K | 309.78K | 14.99M |
| EBIT | -33M | -26.83M | -21.01M | -27.16M | -29.44M | -30.26M | -46.3M | -19.29M | 150.14M |
| Net Interest Income | 105.09K | 34.74K | -464.82K | 82.84K | -1.54K | 299.5K | 2.68M | 2.54M | 1.06M |
| Interest Income | 110.71K | 36.62K | 322.67K | 116.06K | 14.4K | 326.02K | 2.68M | 2.58M | 3.85M |
| Interest Expense | 5.62K | 1.87K | 787.49K | 33.23K | 15.94K | 26.52K | 0 | 36.41K | 2.78M |
| Other Income/Expense | -85.8K | 34.57K | 9.64M | 23.67K | -22.83K | 336.65K | 2.62M | 3.03M | -125K |
| Pretax Income | -33.01M▲ 0% | -26.83M▲ 18.7% | -11.37M▲ 57.6% | -27.2M▼ 139.2% | -29.46M▼ 8.3% | -30.29M▼ 2.8% | -46.34M▼ 53.0% | -19.32M▲ 58.3% | 150.02M▲ 876.3% |
| Pretax Margin % | -10023.45% | -6242.4% | -4014.71% | -11368.54% | -15429.47% | -46305.23% | - | -44.45% | 48.13% |
| Income Tax | -31.27K | 36.44K | 5.06M | -5.17M | -1.25M | -585.62K | 0 | -1.39M | -13.04M |
| Effective Tax Rate % | 0.09% | -0.14% | -44.5% | 19.01% | 4.24% | 1.93% | 0% | 7.22% | -8.69% |
| Net Income | -33.01M▲ 0% | -26.83M▲ 18.7% | -16.43M▲ 38.8% | -22.03M▼ 34.0% | -28.21M▼ 28.1% | -29.7M▼ 5.3% | -46.34M▼ 56.0% | -17.93M▲ 61.3% | 163.06M▲ 1009.4% |
| Net Margin % | -10023.45% | -6242.4% | -5801.29% | -9207.7% | -14774.7% | -45409.9% | - | -41.24% | 52.31% |
| Net Income Growth % | -33.95% | 18.72% | 38.75% | -34.04% | -28.07% | -5.29% | -56.02% | 61.31% | 1009.4% |
| Net Income (Continuing) | -33.01M | -26.83M | -16.43M | -22.03M | -28.21M | -29.7M | -46.34M | -17.93M | 163.06M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.99▲ 0% | -1.51▲ 49.5% | -0.68▲ 55.0% | -0.77▼ 13.2% | -0.75▲ 2.6% | -0.74▲ 1.3% | -0.91▼ 23.0% | -0.30▲ 67.0% | 2.04▲ 780.0% |
| EPS Growth % | 8% | 49.5% | 54.97% | -13.24% | 2.6% | 1.33% | -22.97% | 67.03% | 780% |
| EPS (Basic) | -2.99 | -1.51 | -0.68 | -0.77 | -0.75 | -0.74 | -0.91 | -0.30 | 2.25 |
| Diluted Shares Outstanding | 11.03M | 17.82M | 24.15M | 28.56M | 37.67M | 40.27M | 50.9M | 58.87M | 80.31M |
| Basic Shares Outstanding | 11.03M | 17.82M | 24.15M | 28.56M | 37.61M | 40.14M | 50.9M | 58.87M | 72.03M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
CRMD Balance Sheet
CorMedix Inc. (CRMD) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 13.27M | 18.67M | 29.35M | 48.18M | 66.47M | 59.55M | 79.45M | 114.58M | 350.47M |
| Cash & Short-Term Investments | 11.98M | 17.62M | 28.51M | 46.35M | 65.47M | 59.02M | 76.03M | 51.69M | 149.52M |
| Cash Only | 10.38M | 17.62M | 16.53M | 41.91M | 53.32M | 43.37M | 43.64M | 40.65M | 145.82M |
| Short-Term Investments | 1.6M | 0 | 11.98M | 4.44M | 12.15M | 15.64M | 32.39M | 11.04M | 3.69M |
| Accounts Receivable | 64.15K | 10.9K | 0 | 3.36K | 45.37K | 0 | 0 | 51.65M | 171.23M |
| Days Sales Outstanding | 71.1 | 9.26 | - | 5.12 | 86.73 | - | - | 433.69 | 200.51 |
| Inventory | 594.19K | 428.51K | 338.46K | 143.56K | 3.01K | 0 | 2.11M | 7.6M | 29.72M |
| Days Inventory Outstanding | 1.89K | 394.19 | 331 | 255.81 | 7.37 | - | 3.74K | 869.39 | 301.61 |
| Other Current Assets | 258.2K | 179.67K | 54.83K | 273.52K | 902.05K | -91.3K | 959.67K | 3.48M | 0 |
| Total Non-Current Assets | 186.28K | 160.86K | 126.82K | 1.13M | 2.48M | 2.49M | 2.61M | 4.27M | 425.35M |
| Property, Plant & Equipment | 186.28K | 160.86K | 126.82K | 1.13M | 2.37M | 2.38M | 2.51M | 2.32M | 9.93M |
| Fixed Asset Turnover | 1.77x | 2.67x | 2.23x | 0.21x | 0.08x | 0.03x | - | 18.73x | 31.41x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 30M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.84M | 379.07M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 102.31K | 102.32K | 103.06K | 105.37K | -9.93M |
| Total Assets | 13.45M▲ 0% | 18.83M▲ 39.9% | 29.48M▲ 56.6% | 49.31M▲ 67.3% | 68.95M▲ 39.8% | 62.04M▼ 10.0% | 82.06M▲ 32.3% | 118.85M▲ 44.8% | 826.14M▲ 595.1% |
| Asset Turnover | 0.02x | 0.02x | 0.01x | 0.00x | 0.00x | 0.00x | - | 0.37x | 0.38x |
| Asset Growth % | -38.58% | 39.93% | 56.57% | 67.28% | 39.83% | -10.02% | 32.27% | 44.83% | 595.14% |
| Total Current Liabilities | 6.26M | 7.77M | 5.83M | 4.16M | 5.35M | 6.31M | 11.4M | 33.84M | 174.27M |
| Accounts Payable | 1.81M | 2.59M | 1.02M | 1.13M | 2.21M | 2.2M | 4.28M | 1.72M | 7.88M |
| Days Payables Outstanding | 5.74K | 2.38K | 1K | 2.01K | 5.41K | 215.26K | 7.6K | 196.79 | 80.02 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 88.4K | 11.03K | 2.21K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.61M | 4.06M | 3.51M | 0 | 0 | 0 | 0 | 0 | 152.18M |
| Current Ratio | 2.12x | 2.40x | 5.04x | 11.58x | 12.44x | 9.44x | 6.97x | 3.39x | 2.01x |
| Quick Ratio | 2.02x | 2.35x | 4.98x | 11.54x | 12.43x | 9.44x | 6.78x | 3.16x | 1.84x |
| Cash Conversion Cycle | -3.78K | -1.98K | - | -1.75K | -5.32K | - | - | 1.11K | 422.1 |
| Total Non-Current Liabilities | 0 | 6.13M | 2.68K | 923.71K | 802.43K | 667.63K | 517.01K | 349.09K | 246.57M |
| Long-Term Debt | 0 | 6.13M | 0 | 0 | 0 | 0 | 0 | 0 | 144.63M |
| Capital Lease Obligations | 0 | 0 | 2.68K | 923.71K | 802.43K | 667.63K | 517.01K | 349.09K | 2.84M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 99.1M |
| Total Liabilities | 6.26M | 13.89M | 5.83M | 5.09M | 6.15M | 6.98M | 11.92M | 34.19M | 420.83M |
| Total Debt | 0 | 6.13M | 4.69K | 1.03M | 923.8K | 802.43K | 667.63K | 517.01K | 148.91M |
| Net Debt | -10.38M | -11.5M | -16.52M | -40.87M | -52.39M | -42.57M | -42.98M | -40.13M | 3.09M |
| Debt / Equity | - | - | - | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x | 0.37x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 0.90x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.02x |
| Interest Coverage | -5873.70x | -14323.42x | -26.68x | -817.55x | -1846.86x | -1141.27x | - | -529.83x | 53.97x |
| Total Equity | -152.17M▲ 0% | -178.99M▼ 17.6% | -195.42M▼ 9.2% | 44.22M▲ 122.6% | 62.8M▲ 42.0% | 55.06M▼ 12.3% | 70.14M▲ 27.4% | 84.66M▲ 20.7% | 405.31M▲ 378.8% |
| Equity Growth % | -954.22% | -17.62% | -9.18% | 122.63% | 42% | -12.32% | 27.39% | 20.69% | 378.76% |
| Book Value per Share | -13.80 | -10.05 | -8.09 | 1.55 | 1.67 | 1.37 | 1.38 | 1.44 | 5.05 |
| Total Shareholders' Equity | -152.17M | -178.99M | -195.42M | 44.22M | 62.8M | 55.06M | 70.14M | 84.66M | 405.31M |
| Common Stock | 71.41K | 108.88K | 25.66K | 33.56K | 38.09K | 42.81K | 54.94K | 64.41K | 79K |
| Retained Earnings | -152.17M | -178.99M | -195.42M | -217.45M | -245.66M | -275.36M | -321.7M | -339.63M | -176.57M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 98.43K | 96.52K | 97.26K | 102K | 87.13K | 82.74K | 94.11K | 90.65K | 3K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CRMD Cash Flow Statement
CorMedix Inc. (CRMD) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -28.59M | -23.7M | -15.05M | -21.97M | -21.16M | -24.36M | -38.41M | -50.61M | 175.05M |
| Operating CF Margin % | -8680.48% | -5514.36% | -5313.74% | -9182.61% | -11079.75% | -37238.15% | - | -116.43% | 56.16% |
| Operating CF Growth % | -28.39% | 17.09% | 36.49% | -45.94% | 3.7% | -15.13% | -57.7% | -31.78% | 445.84% |
| Net Income | -33.01M | -26.83M | -16.43M | -22.03M | -28.21M | -29.7M | -46.34M | -17.93M | 163.06M |
| Depreciation & Amortization | 36.89K | 74.22K | 73.29K | 127.96K | 61.89K | 84.62K | 70.75K | 309.78K | 0 |
| Stock-Based Compensation | 1.66M | 1.11M | 2.44M | 2.5M | 5.04M | 4.07M | 5.49M | 6.13M | 0 |
| Deferred Taxes | -4.57M | -3.13M | -578.95K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 4.42M | 3.13M | 1.38M | 78.37K | 115.13K | 124.42K | 134.81K | 284.58K | 4.72M |
| Working Capital Changes | 2.88M | 1.94M | -1.93M | -2.65M | 1.84M | 1.07M | 2.23M | -39.41M | 7.27M |
| Change in Receivables | -47.6K | 51.99K | 10.63K | -3.09K | -44.08K | 42.14K | 0 | -51.79M | -90.92M |
| Change in Inventory | -100.46K | 165.68K | 59.28K | 149.6K | 145.46K | 3.01K | -2.11M | -5.49M | -3.48M |
| Change in Payables | 157.53K | 782.06K | -1.56M | 103.33K | 1.08M | -6.57K | 2.08M | -2.56M | 3.33M |
| Cash from Investing | 10.36M | 1.56M | -12.02M | 7.43M | -9.13M | -3.71M | -17.06M | 21.23M | -308.43M |
| Capital Expenditures | -151.99K | -48.89K | -36.57K | -112.64K | -1.43M | -219.36K | -327.3K | -115.73K | -2.26M |
| CapEx % of Revenue | 46.15% | 11.38% | 12.91% | 47.08% | 746.5% | 335.37% | - | 0.27% | 0.73% |
| Acquisitions | 0 | 0 | 11.98M | 0 | 0 | 0 | 0 | 0 | -308.51M |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 10.51M | 1.6M | -11.98M | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 20.52M | 29.4M | 25.8M | 40.1M | 41.76M | 17.9M | 55.92M | 26.32M | 238.45M |
| Debt Issued (Net) | 0 | 7.5M | 0 | 0 | 0 | 0 | 0 | 0 | 144.08M |
| Equity Issued (Net) | 20.52M | 21.97M | 15.23M | 39.69M | 41.46M | 17.77M | 55.83M | 18.88M | 96.55M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 6.8K | -70.94K | 10.57M | 411.75K | 301.92K | 128.63K | 89.3K | 7.44M | -2.18M |
| Net Change in Cash | 2.32M▲ 0% | 7.24M▲ 212.9% | -1.27M▼ 117.5% | 25.57M▲ 2113.3% | 11.45M▼ 55.2% | -10.18M▼ 188.8% | 448.45K▲ 104.4% | -3.07M▼ 783.9% | 105.07M▲ 3525.7% |
| Free Cash Flow | -28.74M▲ 0% | -23.75M▲ 17.4% | -15.09M▲ 36.5% | -22.08M▼ 46.3% | -22.58M▼ 2.3% | -24.58M▼ 8.8% | -38.74M▼ 57.6% | -50.73M▼ 31.0% | 172.79M▲ 440.6% |
| FCF Margin % | -8726.64% | -5525.74% | -5326.65% | -9229.69% | -11826.24% | -37573.53% | - | -116.7% | 55.43% |
| FCF Growth % | -28.74% | 17.36% | 36.47% | -46.34% | -2.27% | -8.84% | -57.62% | -30.96% | 440.6% |
| FCF per Share | -2.61 | -1.33 | -0.62 | -0.77 | -0.60 | -0.61 | -0.76 | -0.86 | 2.15 |
| FCF Conversion (FCF/Net Income) | 0.87x | 0.88x | 0.92x | 1.00x | 0.75x | 0.82x | 0.83x | 2.82x | 1.07x |
| Interest Paid | 5.62K | 1.87K | 12.55K | 33.23K | 15.94K | 26.52K | 34.3K | 36.41K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CRMD Key Ratios
CorMedix Inc. (CRMD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -95.1% | - | - | - | -49.81% | -52.72% | -50.4% | -74.02% | -23.17% | 66.56% |
| Return on Invested Capital (ROIC) | -116.27% | - | - | - | -609.35% | -321.02% | -200.66% | -185.19% | -46.78% | 49.72% |
| Gross Margin | -63.62% | 65.09% | 7.68% | -31.76% | 14.37% | 22% | 94.29% | - | 92.66% | 88.46% |
| Net Margin | -10996.46% | -10023.45% | -6242.4% | -5801.29% | -9207.7% | -14774.7% | -45409.9% | - | -41.24% | 52.31% |
| Debt / Equity | - | - | - | - | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x | 0.37x |
| Interest Coverage | -18797.58x | -5873.70x | -14323.42x | -26.68x | -817.55x | -1846.86x | -1141.27x | - | -529.83x | 53.97x |
| FCF Conversion | 0.90x | 0.87x | 0.88x | 0.92x | 1.00x | 0.75x | 0.82x | 0.83x | 2.82x | 1.07x |
| Revenue Growth | 6.65% | 46.95% | 30.51% | -34.09% | -15.55% | -20.19% | -65.74% | -100% | - | 617.03% |
CRMD SEC Filings & Documents
CorMedix Inc. (CRMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
CRMD Frequently Asked Questions
CorMedix Inc. (CRMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
CorMedix Inc. (CRMD) reported $311.7M in revenue for fiscal year 2025.
CorMedix Inc. (CRMD) grew revenue by 617.0% over the past year. This is strong growth.
Yes, CorMedix Inc. (CRMD) is profitable, generating $163.1M in net income for fiscal year 2025 (52.3% net margin).
Dividend & Returns
CorMedix Inc. (CRMD) has a return on equity (ROE) of 66.6%. This is excellent, indicating efficient use of shareholder capital.
CorMedix Inc. (CRMD) generated $174.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More CRMD
CorMedix Inc. (CRMD) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates